pre-IPO PHARMA

COMPANY OVERVIEW

Adagene (Suzhou China) is a clinical stage biotech company with innovative antibody discovery and engineering technologies. Utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is developing immuno-oncology antibodies against novel epitopes that give unique product profiles that have potential to succeed where other groups have failed.


LOCATION

  • Suzhou, , China
  • San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.adagene.com


    CAREER WEBSITE

    https://www.adagene.com/?page_id=10980


    SOCIAL MEDIA


    INVESTORS

    6-dimensions-capital eight-road-ventures f-prime-capital-partners gp-healthcare-capital new-world-tmt sequoia-china


    PRESS RELEASES


    Feb 1, 2021

    Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles


    Jan 9, 2020

    Adagene to Present at the 38th Annual J.P. Morgan Healthcare Conference


    Jan 8, 2020

    Adagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic


    Oct 26, 2019

    Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences


    Apr 24, 2019

    ADC Therapeutics and Adagene Announce License Agreement


    For More Press Releases


    Google Analytics Alternative